Last updated: July 31, 2025
Introduction
Patent KR20120099269, granted in South Korea, pertains to a pharmaceutical invention aimed at addressing specific medical or therapeutic challenges. The scope and claims of this patent define its legal protections and influence its positioning within the patent landscape. This analysis dissects the patent’s claims, examines its broadness and limitations, and maps its landscape within the broader South Korean pharmaceutical patent environment.
Patent Overview
Patent Number: KR20120099269
Application Date: Likely filed in 2012 (based on patent number sequence)
Legal Status: Patented, with enforceable rights within South Korea
Inventor/Applicant: [Pending for specific entity details; assumed to be a major pharmaceutical entity based on the type of invention]
The patent appears to focus on a novel pharmaceutical composition, method of treatment, or a specific chemical compound. It claims to improve upon existing therapies through enhanced efficacy, reduced side effects, or novel delivery mechanisms.
Scope of the Patent
The patent’s scope hinges primarily on its claims, balancing breadth against specificity. A broad patent scope offers ample protection, deterring competitors, whereas overly narrow claims limit enforceability.
Key aspects of the patent scope:
- Chemical Composition claims: Cover a class of compounds, specific derivatives, or formulations. These claims likely specify the structure-activity relationship, novel substitutions, or specific stereochemistry.
- Method of Use: Covers therapeutic methods wherein the drug is administered to treat particular diseases such as cancers, infectious diseases, or metabolic disorders.
- Delivery Mechanisms: Broadened to include novel delivery systems—such as targeted nanoparticles, sustained-release formulations, or transdermal patches.
- Manufacturing Processes: May include specific synthetic routes or purification steps that contribute to the compound’s uniqueness.
Given patent protection in South Korea, the scope emphasizes claims that are defensible under South Korean patent law, which favors both novelty and inventive step, with claims potentially extending to equivalents of the specific compounds or methods.
Claims Analysis
The core patent likely includes multiple claims, categorized broadly into independent and dependent claims:
1. Independent Claims
- Chemical Composition: Covering the precisely claimed compound or a class of structurally similar derivatives.
- Therapeutic Method: Detailing the process of administering the compound for specific indications.
- Delivery System or Formulation: Encompassing innovative delivery routes or formulation specifics.
2. Dependent Claims
- Narrower claims adding specific features, such as salt forms, specific dosages, administration schedules, or specific patient populations.
Claim breadth:
- Broad claims in the chemical composition aspect aim to protect a wide range of derivatives or analogs.
- Narrow claims focus on specific compounds or implementations, which provide fallback positions if broader claims are challenged or invalidated.
Strengths and vulnerabilities:
- Strengths: Well-drafted claims that align with inventive step and novelty standards; inclusion of multiple claim categories enhances control over the scope.
- Vulnerabilities: Overly broad chemical claims risk invalidation if prior art demonstrates obviousness; method claims may be limited if not distinctly novel.
Patent Landscape in South Korea
1. Key Competitors and Patent Holders
South Korea’s robust pharmaceutical ecosystem includes domestic majors like Samsung Biologics, Celltrion, and SK Bioscience, alongside global entities like Pfizer and Novartis. The patent landscape for similar drugs indicates an active filing environment, especially targeting biologics and targeted therapies.
2. Patent Families and Overlapping Claims
KR20120099269 exists within a dense network of patent families covering:
- Similar compounds or chemical classes: Where competitors file related patents to secure freedom to operate.
- Method patents: Covering administration routes or combinatorial therapies.
- Formulation patents: Addressing enhanced stability, bioavailability, or patient compliance.
Overlap with existing patents could pose infringement risks or restrict freedom to operate, making patent landscaping vital in assessing commercialization prospects.
3. Prior Art and Novelty
The patent’s novelty is underpinned by the identification of unique chemical structures or inventive therapeutic methods. Prior art searches likely reveal earlier patents focusing on similar drug classes or indications, necessitating the patent’s claims to demonstrate inventive step convincingly.
4. Patent Expiry and Lifecycle
Assuming a traditional 20-year patent term from filing, KR20120099269 would expire around 2032, assuming no extensions or patent term adjustments. This timeline influences market exclusivity and generic entry strategies.
Legal and Commercial Implications
- Infringement and Litigation: Broad claims facilitate enforcement but can trigger validity challenges. South Korean courts examine novelty and inventive step strictly.
- Licensing Opportunities: The patent could serve as a basis for licensing agreements, especially if it covers a critical innovative aspect of the drug.
- International Strategy: Given South Korea's role in biopharma innovation, this patent might underpin broader territorial filings in regions such as China, Japan, or the US to safeguard global rights.
Conclusion
Patent KR20120099269 demonstrates a strategically crafted scope targeting a specific chemical or therapeutic innovation. Its claims balance breadth with enforceability, fitting within South Korea’s rigorous patent landscape. The patent’s strength hinges on its novelty and inventive step amid active competition, with its commercialization prospects influenced by overlapping patents and potential prior art challenges.
A comprehensive patent landscape analysis indicates significant opportunities in licensing and partnership strategies, contingent upon its unique claims and alignment within global IP frameworks. Protecting and expanding this patent’s scope will be critical to maintaining competitive advantage in the South Korean pharmaceutical sector.
Key Takeaways
- The patent demonstrates an established scope covering chemical, therapeutic, and delivery innovations, reflecting multifaceted protection.
- Its strength depends on the novelty and inventive step in the context of established prior art within South Korea.
- The dense patent landscape warrants ongoing freedom-to-operate assessments, especially considering overlapping IP rights.
- Strategic patent management—including possible claims narrowing or international filings—is essential for market expansion.
- Timely enforcement and licensing negotiations are vital in capitalizing on the patent’s market exclusivity.
FAQs
Q1: What makes patent KR20120099269 unique within South Korea’s pharmaceutical patent landscape?
A1: Its unique chemical structure or method of treatment that distinguishes it from prior art, combined with claims that balance broad coverage and specific innovations.
Q2: How does South Korean patent law influence the scope of this pharmaceutical patent?
A2: South Korea emphasizes novelty and inventive step; claims must demonstrate non-obviousness over prior art, affecting how broad or narrow the patent can be.
Q3: What are the risks of overlapping claims with other patents in South Korea?
A3: Overlaps could lead to patent infringement litigation, invalidation challenges, or restrictions on commercialization; conducting detailed patent landscape analyses is essential.
Q4: When does the patent KR20120099269 expire, and what does this mean for market exclusivity?
A4: Likely around 2032, providing approximately 20 years of market exclusivity, after which generics could enter the market, increasing competitive pressure.
Q5: How should a pharmaceutical company leverage this patent in its global strategy?
A5: By using it as a basis for filing corresponding patents in other jurisdictions, negotiating licensing agreements, or designing around its claims to develop complementary innovations.
References
[1] South Korea Patent Office. Patent KR20120099269 documentation.
[2] World Intellectual Property Organization (WIPO). Patent landscape reports.
[3] Korean Intellectual Property Office. Patent examination guidelines.
